Abstract P2-07-11: Prediction of the Oncotype Dx recurrence score (RS) from clinicopathologic factors
IA Voutsadakis, S Thibodeau, M Reed - Cancer Research, 2019 - AACR
Abstract Background: The Oncotype Dx assay is currently used as an aid to therapeutic
decisions for the adjuvant treatment of women with ER-positive, Her2-negative, lymph node …
decisions for the adjuvant treatment of women with ER-positive, Her2-negative, lymph node …
The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer.
AS Abdalla Al-Zawi - Medical Research Journal (2451-2591), 2021 - search.ebscohost.com
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
The effect of oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor–positive early stage breast cancer and correlation with …
JE Joh, NN Esposito, JV Kiluk, C Laronga… - The …, 2011 - academic.oup.com
Abstract Purpose. The Oncotype DX assay predicts likelihood of distant recurrence and
improves patient selection for adjuvant chemotherapy in estrogen receptor–positive (ER …
improves patient selection for adjuvant chemotherapy in estrogen receptor–positive (ER …
A quality improvement initiative on the utility of the Oncotype DX breast cancer assay in a community hospital.
e13072 Background: Since the advent of Oncotype DX (ODX) breast recurrence score (RS)
assay, the use of adjuvant chemotherapy (CT) in the treatment of breast cancer has …
assay, the use of adjuvant chemotherapy (CT) in the treatment of breast cancer has …
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
J Asad, AF Jacobson, A Estabrook, SR Smith… - The American journal of …, 2008 - Elsevier
BACKGROUND: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence
in women with estrogen-receptor–positive, lymph node–negative breast cancer. The …
in women with estrogen-receptor–positive, lymph node–negative breast cancer. The …
[HTML][HTML] Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
Abstract Background The Oncotype DX breast recurrence score has been introduced more
than a decade ago to aid physicians in determining the need for systemic adjuvant …
than a decade ago to aid physicians in determining the need for systemic adjuvant …
The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer
ASA Al-Zawi - Medical Research Journal, 2021 - journals.viamedica.pl
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
Decisions on adjuvant chemotherapy for patients with breast cancer based on clinical and evolving Oncotype DX criteria.
J Zekri, MO Al-Foheidi, MK Alata, AA Rasmy… - 2019 - ascopubs.org
e12009 Background: Oncotype-DX assay recurrence score (ODX-RS) cut-off values have
recently changed in response to the results of the TAILOR-X trial. We aim to explore …
recently changed in response to the results of the TAILOR-X trial. We aim to explore …
Estimation of Risk of Recurrence of Early Stage Estrogen Receptor Positive Breast Carcinoma by Surgical and Medical Oncologists and Pathologists Compared to the …
G Acs, G Acs, N Esposito, J Kiluk, C Laronga, M Lee… - Cancer Research, 2009 - AACR
Background: The decision to use adjuvant chemotherapy in patients with early stage breast
cancer is based in part on the estimation of risk of tumor recurrence by physicians, which …
cancer is based in part on the estimation of risk of tumor recurrence by physicians, which …
Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration.
DR Kazzaz, C Chen, J Shankleton… - Journal of Clinical …, 2011 - ascopubs.org
e11105 Background: The Onco type DX Recurrence Score (RS) is a clinically validated
molecular test that can be used to predict the risk of distant recurrence and the likelihood of …
molecular test that can be used to predict the risk of distant recurrence and the likelihood of …